 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 1 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 1 of 44 
 
 
 
 
Clinical Investigational Plan (CIP) INFORMATION  
Title: Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770089]-Vu System  
CIP Number:  CL00044 
Version Date:  January 30, 2019  
Version:  4.0 
Sponsor:  Motus GI Medical Technologies LTD. 
Address: Keren Hayesod 22, Tirat Carmel, ZIP 3902638, Israel  
Tel: +972 -4-  6214446  
Fax: +972 -4-  6214442  
 
This document is property of MOTUS GI Medical Technologies LTD, its contents are 
CONFIDENTIAL and shall not be disclosed, disseminated, copi[INVESTIGATOR_770090], without a written 
permission. 
 
 
Summary of Changes to CIP  
Version  Section  Description of Change  Reason for Change  
1.0 NA • NA NA -Initial 
2.0 All • Overall changes to wording  
• Changed from Patient to Subject  
• Changed to study design to 
exclude bowel prep as part of the 
study  
• Updated study diagram   
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 2 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 2 of 44 
 
 
 
• Case Report Forms have been 
taken out and will remain 
standalone documents  
3.0 All • Updates to the inclusion and exclusion criteria  
• Updates on wording  Updates based on Interim Analysis  
4.0 Study design • Expanded enrollment per site from 25 to 35  Due to enrollment delays  
 
 
 
  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 3 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 3 of 44 
 
 
 
1.0 Signature [CONTACT_770130]: Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770089]-Vu System  
CIP Number:  CL00044 
Version Date:  January 30, 2019  
Version:  4.[ADDRESS_1056783] the study as described in the protocol and in accordance 
with the relevant laws/regulations and standards.  
 
 ________________________    ____________________________    ______________________ 
Name  [CONTACT_770131]:  Document No.   Version  Page 4 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 4 of 44 
 
 
 
2.0 Table of Contents  
1.0 Signature [CONTACT_3490]  .................................................................................................................... 3 
2.0 Table of Contents  ................................................................................................................ 4 
3.0 Protocol Synopsis ................................................................................................................ 7 
4.0 Acronyms and Definitions  ................................................................................................ 10 
5.0 Introduction ....................................................................................................................... 11 
5.1 Background  .................................................................................................................... 11 
6.0 Study Device  ..................................................................................................................... 12 
6.1 General Description ........................................................................................................ 12 
6.1.1  Work Station (WS)  ................................................................................................. 13 
6.1.2  Oversleeve ............................................................................................................... 14 
6.1.3  WS Con nector  ......................................................................................................... 15 
6.1.4  Ancillary Apparatus  ................................................................................................ 15 
6.2 Pre-clinical data  .............................................................................................................. 16 
6.3 Clinical data to Date  ....................................................................................................... 16 
7.0 Risk/Benefit Analysis  ....................................................................................................... [ADDRESS_1056784] .................................................................................... 19 
8.0 Study Objectives  ............................................................................................................... 19 
8.1 Primary objective  ........................................................................................................... 19 
8.2 Secondary objectives:  ..................................................................................................... 19 
9.0 Study Endpoints  ................................................................................................................ 20 
9.1 Primary endpoints  .......................................................................................................... 20 
9.2 Secondary endpoints  ...................................................................................................... 20 
10.0  Study Design ..................................................................................................................... 20 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 5 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056785] Selection and Enrollment  ..................................................................................... 22 
11.1  Inclusion Criteria  ........................................................................................................ 22 
11.2  Exclusion Criteria  ....................................................................................................... 22 
11.3  Withdrawal Criteria  .................................................................................................... 23 
11.4  Selection of Investigators and Training  ...................................................................... 23 
12.0  Study Procedures  .............................................................................................................. 24 
12.1  Screening and Informed Consent  ............................................................................... 24 
12.2  Randomization ............................................................................................................ 25 
12.3  Screen Failures  ........................................................................................................... 25 
12.4  Colon Preparation ....................................................................................................... 25 
12.5  Colonoscopy procedure  .............................................................................................. 25 
13.0  Statistical Analysis  ............................................................................................................ 27 
13.1  Sample Size Determination  ........................................................................................ 27 
13.2  Description of statistical methods ............................................................................... 28 
13.3  Primary Endpoint Analysis  ......................................................................................... 28 
13.4  Secondary Endpoints Analysis  ................................................................................... 28 
Safety Analysis  ......................................................................................................................... 28 
Efficacy Analysis  ...................................................................................................................... 29 
13.5  Analysis Populations  .................................................................................................. 29 
13.6  Interim Analyses  ......................................................................................................... 30 
14.0  Adverse Events (AEs) and Complications  ........................................................................ 30 
14.1  Adverse Event (AE)  .................................................................................................... 30 
14.2  Serious Adverse Event (SAE)  .................................................................................... [ADDRESS_1056786] (ADE)  .................................................................................... [ADDRESS_1056787] (SADE)  ..................................................................... 31 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 6 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056788] ([LOCATION_003]DE)  .......................................... [ADDRESS_1056789] (IRB)/Ethics Committee (EC)  ........................................ [ADDRESS_1056790] Informed Consent  .......................................................................................... 36 
15.5  Insurance  ..................................................................................................................... 36 
15.6  Confidentiality  ............................................................................................................ 36 
15.7  Use of Data and Publications ...................................................................................... 37 
16.0  Monitoring Procedures ...................................................................................................... 38 
16.1  Data Collection and Processing .................................................................................. 39 
17.0  Study Supplies and Device Accountability....................................................................... 40 
17.1  Packaging .................................................................................................................... 40 
17.2  Labeling  ...................................................................................................................... 40 
17.3  Inventory Control  ....................................................................................................... 40 
17.4  Retention of Records  .................................................................................................. 41 
17.5  Study Completion/Termination of Study ................................................................... [ADDRESS_1056791] Information ......................................................................................... 42 
19.0  References  ......................................................................................................................... 42 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 7 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 7 of 44 
 
 
 
20.0  Appendi xes A: Study Design and Schedule of Assessment  ............................................. 43 
21.0  Appendix B: [LOCATION_011] Bowel Preparation Scale  ................................................................. 44 
 
3.0 Protocol Synopsis  
Study  Summary  
Study Purpose  The aim of this study is to evaluate the potential improvement in 
colonoscopy procedure's  outcomes when using the Pure -Vu System in 
hospi[INVESTIGATOR_770091].  
Objective  The primary objective  of this study is  to evaluate t he bowel cleansing 
after Pure -Vu use i n hospi[INVESTIGATOR_26328] , which may increase the 
likelihood of a  successful colonoscopy examination.  
Study procedures   Eligible subjects will be consented  and enrolled   
 Following standard bowel preparation, the nurse  or study coordinator  
will be asked to complete a questionnaire about the subjects’ 
baseline preparation  condition prior  to the colonoscopy procedure.  
 Subjects will undergo colonoscopy procedure  with Pure -Vu System . 
 In case of inadequate bowel preparation  as defined as  BBPS < [ADDRESS_1056792] on e of the colon segments, prior Pure -Vu use , the physician will 
complete a questionnaire on the patient’s  management standard of 
care assuming the absence of Pure- Vu.   
 
Protocol Number  CL00044 
Protocol Title  Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770092] -
Vu System  Ver. 4.0 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 8 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 8 of 44 
 
 
 
Study Sponsor  Motus GI Medical Technologies,  
Keren Hayesod 22, Tirat Carmel, ZIP 3902638, Israel  
Tel: +972 (4) 6214446/103 Fax: +972 (4) [ADDRESS_1056793]-market  
510 (k) Number  K181437 Class II  
Study Location  [LOCATION_002]  and Europe  
Study Duration  Study period will last approx. [ADDRESS_1056794] colonoscopy  
procedure and meet the eligibility criteria.  
Determination of Sample Size This is a pi[INVESTIGATOR_770093] 100 subjects ; no statistical 
considerations were made to determine the sample size.  
Planned # of Sites  Up to 6 clinical sites  
Primary Endpoint  The rate of improved cleansing level per segment will be evaluated by [CONTACT_770110] ( BBPS ) index .  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 9 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 9 of 44 
 
 
 
Secondary Outcomes  The following secondary outcomes will be determined:  
• Type, incidence, severity, relationship and duration of adverse 
events.  
• Cecum intubation rate  
• Proportion of subjects with successful colonoscopy for the 
intended indication in the first attempt.  
Randomization  NA- single arm  
Eligibility Criteria  Inclusion Criteria  
1. Hospi[INVESTIGATOR_770094] a screening, 
diagnostic, surveillance or therapeutic colonoscopy  
2. Subjects ’ age > [ADDRESS_1056795]  has signed the informed consent  
Exclusion Criteria  
1. Subjects  with known Inflammatory Bowel Disease and / or 
active Colitis  
2. Subjects  with  active diverticulitis  
3. Subjects  with known or detected (during colonoscopy) bowel 
obstruction 
4. Subjects  with ascites Child Pugh C  
5. Subjects  who are [ADDRESS_1056796] -transplant  
6. Subjects under active IV inotropic medications  
7. Subjects  with LVAD 
8. Subjects with known coagulation disorder (INR ≥ 2 or platelets 
<50,000)  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 10 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056797] barium  enema  9. Subjects with medical and/or hemodynamic instability.  
10. Pregnancy (as stated by [CONTACT_1130] ) or breast feeding  
11. Subjects with altered mental status/inability to provide 
informed consent  
12. Subject s who have participated in another interventional 
clinical study in the last [ADDRESS_1056798] 45 subjects  enrolled  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 11 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056799] common cancer 
in women worldwide  (2). In the [LOCATION_002], approximately 134,490 new cases are estimated 
for 2016 with approximately 49,190 deaths (8.0% of all cancer deaths) ( 3). Because colorectal 
cancer tends to develop slowly, screening and early detection can significantly reduce both the incidence and associated mortality of the disease ( 4).  
Optical colonoscopy (OC) is considered the gold standard method for the evaluation of subjects 
with suspected colonic disease. A key factor for ensuring high quality colonoscopy and 
successful screening is good colon preparation.  Bowel preparation prior to colonoscopy is one 
of the major barriers to patient compliance estimated as many as 38% of patients do not complete the bowel preparation due to palatability and/or intolerance to the large volume. Inadequate preparation is a major obstacle for achieving a high -quality colonoscopy ( 6).  
Inpatient status is one of several factors associated with poor bowel preparation leading to 
incomplete colonoscopy procedures, which in t urn may cause increased patient morbidity, 
missed pathology, prolonged hospi[INVESTIGATOR_770095]. According to results from a 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 12 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 12 of 44 
 
 
 
prospective study by [CONTACT_770111]. (7) involving a cohort of [ADDRESS_1056800] 
colonoscope with a length of 1630mm – 1710mm and a The Oversleeve, which fits over the 
colonoscope , is connected to an external workstation, generates fluid jets to break up the feces. 
The fecal matter & fluids are removed through the evacuation channels of the Oversleeve device 
into an external waste receptacle.  
This study is designed to evaluate the potential improvement s in colonoscopy procedure  
outcomes when using the Pure -Vu System in hospi[INVESTIGATOR_770096] .  
6.0 Study Device 
6.1 General  Description  
The Pure -Vu System is Food and Drug Administration (FDA) cleared  device, intended to 
connect to standard colonoscopes to help facilitate intra -procedural cleaning of a poorly prepared 
colon by [CONTACT_770112] (water), feces and other bodily fluids and matter, e.g. blood.  
The Pure -Vu System comprises the following components:  
• The Pure -Vu Workstation (WS) -  controls the flow of gas (e.g. air) and water or saline to 
the Oversleeve device and  the evacuation of fecal matter and fluids out of the body. 
• The disposable Oversleeve  is mounted on top of  the colonoscope  allowing the physician 
to clean the colon. The Oversleeve is  connected  to WS via the WS Connector (WSC).  
• The disposable WS Connector is mounted onto the front panel of the WS and connects  to 
the irrigation  and sensing  lines  of the Oversleeve.  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 13 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 13 of 44 
 
 
 
• The loading fixture is an ancillary device that is used to aid in loading the device on the 
colonoscope.  
• External reservoir for collecting the ev acuated fecal matter and fluids  
• External foot pedals that operate the cleansing and evacuation process to be used by [CONTACT_1275]. 
Below is a drawing showing the various components of the system and where they connect to 
each other.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Pure- Vu Workstation – General design & components  
A detailed description of the system components, its principles of operation, dimensions and 
packaging is elaborated in the I nstruction for use (IFU) . 
6.1.1 Work Station (WS) 
The WS controls the flow of gas (e.g. air) and water or saline to the Oversleeve device and the 
evacuation of fecal matter and fluids out of the body. The WS has the following main functions:  

 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 14 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 14 of 44 
 
 
 
• Cleansing: Creates an irrigation stream, which is a mixture  of liquid (water or saline) and 
air into the colon to break up fecal matter. The irrigation of air and liquid (water or 
saline) is referred to as “cleansing jets”. The cleansing has three modes, high, medium 
and low with medium being the default setting. The physician can operate the system as 
per his clinical judgment. It is important to note that the evacuation function noted below 
is active during cleansing so that fluid is input and removed from the colon 
simultaneously. 
• Evacuation: Removes fecal matter and fluids out of the colon. The evacuation function is 
active during the cleansing as previously noted and can also be used independently. During evacuation the system senses the pressure in the evacuation channel of the 
Oversleeve and if the pressure goes below pre -set limits will automatically reverse the 
flow to purge a potential blockage and then switch back to continue evacuation. The user 
also has the ability to manually purge the evacuation channel as well. 
• User interface: Consists of actuators an d indicators on the WS itself as well as a foot 
pedal to activate the main functions of the system so that user s’ hands are free to 
manipulate the colonoscope in a standard fashion.  
6.1.2 Oversleeve  
The Oversleeve is mounted on top of the colonoscope and is connected to WS via the WS Connector . The Oversleeve includes the following main components:  
• Tubing: Six (6) tubes (2 Pebax and 4 PVC) that support the irrigation, evacuation and sensing functions of the system. 
• Cleansing and Evacuation head: The Oversleeve’s distal part which contains irrigation 
ports, evacuation openings, and colon sensing port. 
• Inner sleeve: This sleeve attaches the Oversleeve to the colonoscope along its length. 
This sleeve is inflated to allow the colonoscope to be inserted through it and then deflated 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 15 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 15 of 44 
 
 
 
to hold onto the colonoscope when it is navigated through the colon. The inner sleeve is 
also attached to the outer sleeve noted below on one side. 
• Outer sleeve: This sleeve covers the entire p ortion of the device that goes inside the colon 
keepi[INVESTIGATOR_770097] a smooth surface to interface with the wall of the colon. The distal 28 cm of the sleeve is coated with hydrophilic coating to provide a 
lubricious surface to aid i n advancing the system through the colon.  
• Inflation connector: Provides the port to pressurize the inner sleeve during the loading of 
the colonoscope and provides the entry location for the colonoscope to be inserted into the Oversleeve.  
6.1.[ADDRESS_1056801] bag of saline or water to the 
irrigation line and the evacuation line to the recommended waste tank.  
6.1.4 Ancillary Apparatus  
The final part of the system is  ancillary apparatus to aid in loading the device on a colonoscope.  
• The loading apparatus consists of a pressure source and a distal sealing plug to facilitate inflation of the inner sleeve of the device as well as a base to keep the Oversleeve in a stable position to allow insertion of the colonoscope through the inner sleeve. 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 16 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 16 of 44 
 
 
 
6.2 Pre-clinical data  
The Pure -Vu system was used by [CONTACT_770113] 35 Yorkshire cross 
swine (66% female) that received a reduced bowel preparation t o ensure an inadequate bowel 
preparation at baseline. Prior to the colonoscopy the Pure -Vu was attached to the colonoscope 
and the baseline prep was assessed during insertion.  The Pure -Vu system was then employed to 
cleanse the colon and the prep was then assessed post -Pure-Vu use.  
No adverse effects and no failed or prematurely terminated cases were noted.  Fourteen percent 
of the swine colons were adequately prepped at baseline (mean BBPS score 0.5 ± 0.7) and 
improved to 100% after use of Pure -Vu (p <0.001) (mean BBPS score 3.0 ± 0.0).  The 
physicians found Pure -Vu easy and intuitive to operate.  The Pure- Vu system effectively cleaned 
inadequately prepped swine colons and found to be easy to use.   
6.3 Clinical data  to Date  
The Pure -Vu System was evaluated  in ninety- seven  subjects (54% males) from five sites using 
similar protocol.  
Pure-Vu was used in subjects indicated  for a screening, diagnostic or surveillance  colonoscopy.  
To ensure an inadequately prepped colon, subjects underwent a reduced preparation consisting of 
dietary restrictions (no dried fruit, seeds or nuts) starting 2 days prior to the colonoscopy, an 18 to 24 hour clear liquid diet and a split dose of 20mg Bisacodyl. 
The cleansing quality was evaluated before and after use of the Pure -Vu System with the [LOCATION_011] 
Bowel Preparation Score (BBPS) (1). 
Two subjects were excluded from the analysis due to the followings:   One subject had breakfast 
on day of procedure and therefore was excluded from the cleansing efficacy and usability 
analysis due to non- compliance with the pre -procedural prep regimen.  The other subject  was 
excluded because the device could no t reach beyond the sigmoid colon due to the subject’s  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 17 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056802] the sigmoid and into the cecum.  
The Pure -Vu signifi cantly increased the number of subjects with an adequate cleansing level 
(BBPS >= 2 for all 3 colon segments) from 25%; CI 95% [17%, 35%] at baseline to 99%; CI 95% [9 4%, 100%] after Pure -Vu. Cecum intubation rate was 98%; CI 95% [94%, 100%]). Mean 
post-treatment BBPS score was 8. 7 ± 1.0 vs. 3.9 ± 2.2 prior to Pure -Vu use. Physicians  were 
satisfied with the device’s use. No major difficulties were experienced when performing 
polypectomy and no serious adverse events were reported.  
7.0 Risk/Benefit Analys is 
7.[ADDRESS_1056803] colonoscope during a colonoscopy 
procedure. Hence, the complications associated with using the Pure -Vu are antici pated to be 
similar to those associated with the colonoscopy procedure.  As with any colonoscopy procedure, 
when using the Pure -Vu there is some risk of bowel perforation, pain, infection or  bleeding. 
Although the risks of the procedure with the Pure -Vu Sy stem are expected to be comparable to 
conventional colonoscope (0.35%), the device is an add- on to a standard colonoscope.  
The Pure -Vu system  was tested in an animal study including 35 pi[INVESTIGATOR_770098] 97 subjects.  
No major complication  or serious adverse events occurred within the course of those studies.  
In addition, these clinical studies demonstrated an exc ellent cleansing effectiveness; Pure- Vu 
improved the cleansing level from 25% at baseline to 99% after the cleansing was operated and 
in 98% of the subjects  the cecum was reached and the procedures completed successfully.  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 18 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056804] been implemented.  
The residual risk is evaluated according to the following:  
• Acceptable Residual risk includes all RPN ≤ 9.  
• Risks rated 10- 16 will be acceptable if the risk benefit ratio justifies it.  
All risks of using Pure -Vu were mitigated by [CONTACT_770114] 
[ZIP_CODE]:2012.  
The mitigation to the risks associated with the investigational device includes but is not limited 
to the followings:  
• Smooth head shape that contains lumens for cleansing jets and evacuation. The lumens' 
sizes  were optimized to ensure the safety of the subjects  along with effective cleansing.  
• The Pure -Vu Over sleeves are made from a flexible and low friction material to allow 
ease of advancement through the colon and to minimize any impact to the steering angle 
of the colonoscope.  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 19 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 19 of 44 
 
 
 
• Hydr ophilic coating at the distal 28cm of the outer sleeve to creat e a lubricious surface  to 
aid in insertion and advancement.  
• Cleansing procedure can be operated in 3 modes (low, medium, high), where the 
physician can control the intensity of cleansing jets to ensure effective cleansing.  
The potential residual risk following the mitigations  are all acceptable (for more details please 
refer to "Risk analysis report").  
7.[ADDRESS_1056805] of care procedure.  
8.0 Study Objectives  
8.1 Primary objective  
To evaluate the improvement of bowel cleansing after Pure -Vu use in hospi[INVESTIGATOR_770099] a successful colonoscopy examination.  
8.2 Secondary objectives:  
o To evaluate the safety related to the Pure- Vu System. 
o To evaluate the potential improvement in hospi[INVESTIGATOR_26328]’ outcomes when using the 
Pure-Vu System . 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 20 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 20 of 44 
 
 
 
9.0 Study Endpoints  
9.1 Primary endpoints  
The rate of improved cleansing level per segment will be evaluated by [CONTACT_770115] (1) scoring 
index pre - and post - Pure -Vu use during a colonoscopy examination.  
9.2 Secondary endpoints  
The following endpoints will be evaluated per study arm:  
o Type, incidence, severity, and duration of adverse events. 
o Cecum intubation rate  
o Proportion of subjects with successful colonoscopy with Pure -Vu for the intended 
indication in the first attempt.  
10.0  Study Design  
This multicenter, prospective, single arm  study will include up to 100 subjects ( up to [ADDRESS_1056806] s 
per site), aimed at evaluating the performance of the Pure -Vu System in cleansing hospi[INVESTIGATOR_770100] ' colon who are indicated for standard colonoscopy procedure .  Subjects will be enrolled 
at up to 6 clinical sites in the [LOCATION_002]  and Europe  
 Subject consent will be obtained 
 Prior to the colonoscopy procedure, the nurse  or study coordinator  will be asked to 
complete a questionnaire including the subjects' bowel preparation type, volume, duration and overall preparation condition.  
 The subject  will undergo the colonoscopy procedure with the Pure -Vu system .  
 In case of inadequate bowel preparation defined as  BBPS  score less than [ADDRESS_1056807] one  
of the colon segments  prior  Pure -Vu use , the physician will complete a questionnaire on 
the patient’s management standard of care assuming the absence of Pure -Vu.   
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 21 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 21 of 44 
 
 
 
 Following the colonoscopy with Pure -Vu a follow -up evaluation will be conducted at 48 
hours (± 48 hours) to assess subject’s well -being and capture any adverse events. If the 
subject  is no longer hospi[INVESTIGATOR_057], the follow up will be conducted by a telephone call.  
Study F lowchart  
 
 
  
      
 
           
 Adequate                                                                             Ina dequate   
           B owel preparation                               B owel preparation  
 
 
        Selected Study 
Population  
Bowel Preparation as 
standard of care  
Fill out patient 
cleansing condition 
 
 
Fill-in patient 
management questionnaire  Colonoscopy with Pure -
Vu System  
 
Capture Procedure 
Outcomes  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 22 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056808] will sign the sites’ designated IRB approved 
informed consent form (ICF).   Enrollment of up to 100 subjects is planned.  
Subjects’ participation in the study will last approximately  3 days, including the procedure day, 
and the follow up period.  
Subjects will be considered for the study if they meet the specific inclusion/exclusion criteria. 
The criteria for enrollment must be followed  explicitly.  
11.1 Inclusion Criteria  
1. Hospi[INVESTIGATOR_770094] a screening, diagnostic, surveillance or 
therapeutic colonoscopy  
2. Subjects ’ age > [ADDRESS_1056809]  has signed the informed consent  
11.2 Exclusion Criteria  
1. Subjects  with known Inflammatory Bowel Disease and / or active Colitis  
2. Subjects  with active diverticulitis  
3. Subjects  with known or detected (during colonoscopy) bowel obstruction  
4. Subjects  with ascites Child Pugh C  
5. Subjects  who are [ADDRESS_1056810] -transplant  
6. Subjects  under active IV inotropic medications  
7. Subjects  with LVAD 
8. Subjects with known coagulation disorder (INR ≥ 2 or platelets <50,000)  
9. Subjects with medical and/or hemodynamic instability.  
10. Pregnancy (as stated by [CONTACT_27720] ) or breast feeding  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 23 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 23 of 44 
 
 
 
11. Subjects with altered mental status/inability to provide informed consent  
12. Subjects  who have participated in another interventional clinical study in the last [ADDRESS_1056811] from the study at any time 
for the following reasons:  
 Severe side effects clearly related to the study device.  
 Presence or appearance of exclusion criteria.  
 Appearance of accompanying diseases rendering further participation in the study impossible.  
 A significant protocol violation, as determined either by [CONTACT_103708]  
 Subject noncompliant with investigational procedures  
The sponsor must be informed in each wit hdrawal case. The reason for withdrawal must be 
recorded in the CRF and in the subject’s study file.  
11.[ADDRESS_1056812] -certified gastroenterologists in accordance with US and hospi[INVESTIGATOR_770101]. Physicians in training (residents, 
fellows) and physician assistants may assist the Study Investigator in any aspect of the procedure 
as per standard procedures and practices at his/her institution.  
Each Invest igator participating in the clinical trial and the associated clinical study staff will 
receive training on the clinical protocol. This includes training on AE reporting, case report form 
(CRF) completion, and Good Clinical Practice (GCP), as well as the d evice and system 
(including procedural use, device characteristics, shelf life and storage requirements, warnings, 
and precautions).  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 24 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 24 of 44 
 
 
 
12.0  Study Procedures  
12.1 Screening  and Informed Consent  
A screening/baseline assessment will be performed prior to the scheduled Pure-Vu procedure to 
ensure  subject’s eligibility  and willingness to participate in the study.  
At the screening visit, s ubjects will be approached to obtain written informed consent prior to 
any study specific proc edures being performed. The purpose of the study and the benefits and 
risks of the procedures will be explained to the subject and the consent process must be 
documented accordingly in the medical records . Subjects who agree to study participation must 
sign an I RB-approved ICF. Subjects will be informed that their participation in this study is 
voluntary and they may refuse to participate or discontinue from the study at any time . Subjects 
will be given the opportunity to ask the inves tigator questions so that they are adequately 
informed about the research. A copy of the signed informed consent must be provided to the 
subject and the informed consent process will be documented in source documents. 
If new information becomes available t hat may affect a subject’s decision to continue to take part 
in the study, this information will be discussed with the subject by [CONTACT_093]. The following assessments will be performed prior to the scheduled procedure and the results 
recorded on the  appropriate subject CRFs:  
• Verification of eligibility criteria and subject risk per guidelines  
• Demographics (age, gender, height, weight)  
• Surgical and medical history (prior abdominal surgery, GI symptoms)  
• General medical history will be assessed based  on the subject’s clinical condition  
Subjects  who were found to be ineligible for the study following signature [CONTACT_770132].  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 25 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 25 of 44 
 
 
 
12.2 Randomization  
NA –Single study arm  
12.[ADDRESS_1056813] “Enr ollment and Visit Log” will be completed and the subject eligibility section in visit 
1 as well as a "Study Completion" form will be completed in the CRF.   
12.[ADDRESS_1056814] completes the bowel prep prior to the colonoscopy procedure  for the 
study.
 
12.5 Colonoscopy procedure   
Pre-Examination Procedures  
• Verify eligibility checked and informed consent was obtained after explaining all risks, 
benefits, and alternatives to the subject . 
• Verify that the study coordinator /nurse has completed  the questionnaire regarding the 
subject ’s bowel cleansing  condition. 
• Verify all background/clinical information, demographic and medical history was 
documented  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 26 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 26 of 44 
 
 
 
• Verify all connections and assembles are properly attached  (see Instructions for Use )  
• Verify device works properly (see Instructions for Use)  
• Place and prepare the subject for the colonoscopy procedure.  
Colonoscopy Procedures  
The insertion dur ing the colonoscopy procedure will be performed by [CONTACT_770116](s), experienced in GI endoscopy according to local standard of care. The withdrawal 
part of the colonoscopy procedure will be performed as per the clinical investigator(s) direction . 
Physicians in training (residents, fellows) and physician assistants may assist the Study 
Investigator in any aspect of this part of the procedure as per standard procedures and practices at 
his/her institution. In cases where upper endoscopy is planned, it will be conducted per the 
physician’s discretion.  Anesthesia will be applied as well per the standard of care. In order to 
ensure correct operation of the Pure -Vu System a Motus GI representative may attend th e 
procedure.  Pure -Vu System operation is described in the Instruction for Use.   
 
The colon preparation level for each colorectal segment (ascending, transverse and descending) 
before the cleansing operation during the insertion phase will be evaluated using the BBPS 
scoring index (Appendix B ). 
In case of inadequat e bowel preparation de fined as  BBPS less than [ADDRESS_1056815] of care assuming absence of the Pure -Vu System .  
Once the procedure is completed, relevant data will be recorded on the CRF in addition, findings, 
diagnosis  as well as Physician questionnaire will be recorded/completed.  
The colonoscopy examination with the Pure -Vu will be recorded on digital media . Only the 
subject study ID and initials should appear in the recorded video.  
The cecum will be documented in a pi[INVESTIGATOR_1103] , if applicable . 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 27 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 27 of 44 
 
 
 
All optical colonoscopy still pi[INVESTIGATOR_770102] a digital format. Quality copi[INVESTIGATOR_770103] . 
These videos and pi[INVESTIGATOR_770104], for example, 
provide further information about observed lesions or to assess study quality. 
Specific situations occurring during colonoscopy  
• If the attempt to reach the cecum is failed, the investigator shall perform the procedure 
with a pediatric or any other colonoscope he/she may choose without Pure -Vu. The 
subject will complete the study as planned.  
• If a medical condition requiring treatment is detected during colonoscopy, the subject 
will be treated as per the standard care.  
Post-Examination Follow -up 
Subjects  will be transferred to recovery room for observation per clinical site’s  colonoscopy 
protocol  and will continue his/her medical flow as per the standard of care . Follow -up will be 
conducted 2 business days  (+/- 48 hours)  after the procedure to verify that there has been no 
change in their well -being. Any AE will be documented in the CRF.  
Before a subject is considered “lost to follow -up”, there must be at least two documented 
attempts to contact [CONTACT_19578].  
13.0  Statistical Analysis  
13.1 Sample Size Determination  
This is a pi[INVESTIGATOR_770105] 100 subjects ; no statistical considerations were made 
to determine the sample size.  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 28 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056816] s.  Summary statistics (mean, standard deviation, median, minimum and maximum for 
quantitative variables) will be presented for the total study population. Frequency tables for 
qualitative data will be provided.    
Any deviation from specified statistical plan will be in addition to “per protocol” analysis and will 
be reported as such. Intent -To-Treat and Post -hoc analysis will be conducted according to the 
existing data gathered, if necessary.   
13.3 Primary Endpoint  Analysis  
The primary endpoint is improving the bowel cleansing level, as determined by [CONTACT_770117], assessed per segment (cecum  and ascending  / transverse /  descending , sigmoid and 
rectum).  
The primary statistical hypothesis is that the cleansing level post Pure -Vu procedure will be 
significantly improve d as compared to the cleansing level pre procedure (prior the Pure -Vu use).  
The primary performance assessment will be based on data from all colon segments observed 
during the colonoscopy procedure.  
The cou nt and percentage of segments and subjects with improved BBPS after the Pure -Vu 
cleansing procedure will be presented together with 95% confidence intervals. 
13.[ADDRESS_1056817] of all subjects  who were enrolled into the study. 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 29 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 29 of 44 
 
 
 
Individual listings of adverse events including type , report ed term, seriousness, duration, 
relationship to the study device, severity and the adverse events outcome will be provided for the 
total population.  AEs will be summarized using frequency counts and percentages.  
13.4.2 Efficacy Analys is 
Cecal Intubation Rate  
The count and percentage of subjects  for which cecum could be reached by [CONTACT_770118] -Vu will be presented together with 95% confidence intervals.  
Proportion of subjects with successful colonoscopy at first attempt  
Successful colonoscopy a t first attempt is defined as complete procedure conducted as schedule d 
for the intended indication. 
Frequency counts, percentages, and 95% confidence intervals will be provided.  In addition, the 
above proportion will be compared vs. the proportion of subjects  that would have under went  a 
complete procedure at first attempt assuming absence of the Pure- Vu System  (as per the data to be 
captured by [CONTACT_770119] ).   Chi-square or Fisher’s exact test, as appropriate, 
will be performed to evaluate the difference between the two clinical set -ups. 
13.[ADDRESS_1056818] the Pure- Vu inserted will be include d in the safety analysis. 
Individual listings of withdrawal / technical failure including descriptive information will be 
provided. 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 30 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 30 of 44 
 
 
 
13.6 Interim Analyses  
An interim analysis is planned after  procedure  completion  of 45 subjects  aims to verify the 
recruitment pace and the study flow . 
14.0  Adverse Events (AEs) and  Complications  
AE and AE subcategories are defined per ISO14155:2011, as described below. 
14.1 Adverse Event (AE)  
An AE is any untoward medical occurrence, unintended disease or injury, or untoward clinical 
signs (including abnormal laboratory findings) in subjects, whether or not related to the 
investigational medical device.  
This definition includes events related to th e investigational medical device or the comparator and 
the procedures involved.  
AEs will be collected starting from the time subject is enrolled until the follow -up period is 
completed . 
14.2 Serious Adverse Event (SAE)  
A Serious AE (SAE)  is an AE  that has  
a) Led  to death,  
b) Led  to serious deterioration in the health of the subject, that either resulted in 
1) A life-threatening illness or injury, or  
2) A permanent impairment of a body structure or a body function, or  
3) In-patient  or prolonged hos pi[INVESTIGATOR_059], or  
4) Medical  or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function, 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 31 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 31 of 44 
 
 
 
c) Led  to fetal distress, fetal death or a congenital abnormality or birth defect  
NOTE: Plann ed hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_232415], without serious deterioration in health, is not considered a n SAE . 
Some important medical events, although they may not result in death, be life -threatening, or 
require hospi[INVESTIGATOR_770106], based upon appropriate medical 
judgment, they are felt to jeopardize the subject and may require medical or surgical intervention 
to prevent one of the outcomes listed above.   
Life threatening means that the subject was, in the view of the investigator, at immediate risk of 
death from the reaction as it occurred . This does not include an AE  that, if more severe, might have 
caused death.  
Disability means a substantial disruption of a person’s ability to conduct normal life’s functions .  
14.[ADDRESS_1056819] (ADE)  
An Adverse Device Effect (ADE) is an AE  related to the use of an investigational medical device.  
This definition includes AE s resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the investigational 
medical device.  
This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device.  
14.[ADDRESS_1056820] (SADE)   
A Serious Adverse Device Effect is an adverse device effect that has resulted in any of the consequences characteristic of an SAE . 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 32 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056821] ([LOCATION_003]DE)  
An Unanticipated Serious Adverse Device Effect is a serious adverse device effect which by [CONTACT_47720], incidence, severity,  or outcome has not been identified in the current version of the risk 
analysis report.  
14.6 Adverse Event Severity Classification  
 Severity will be defined according to the following criteria:  
An AE can be classified as severe and not deemed a SAE . Similarly, a SAE is not automatically 
severe in nature.  
14.[ADDRESS_1056822] administration will be determined as follows:  
• No Relationship:  No relationship between the AE and the administration of study 
treatment and a known relationship to other etiologies such as concomitant medications , 
procedure, or subject’s clinical state.  
• Possible Relationship: An AE  that follows a reasonable temporal sequence from 
administration of the study treatment and follows a known response pattern to the study 
treatment but could have been produced by [CONTACT_2299]’s clinical state or by [CONTACT_43596][INVESTIGATOR_014].  
• Probable Relationshi p: An AE  that follows a reasonable temporal sequence from 
administration of the study treatment; follows a known response pattern to the study 
treatment; and cannot be reasonably explained by [CONTACT_228128]’s clinical state or  by [CONTACT_43593][INVESTIGATOR_014].  Mild  Awareness of event, but easily tolerated  
Moderate  Discomfort enough to cause some interference with activities of daily living (ADL)  
Severe  Incapacitating, with an inability to perform ADL  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 33 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 33 of 44 
 
 
 
• Definite Relationship:  An AE  that follows a plausible temporal sequence from 
administration of the study treatment and follows a known response pattern to the study 
treatment . The reaction cannot be reasonably explained by [CONTACT_770120]’s clinical state or other modes of therapy administered to the subject. 
• Unknown/Impossible to Determine:  Given the information available, sequence and 
timing of events, it is unknown or impossible to determine the relationship of the AE  
with the study treatment.  
14.8 Adverse Event  Outcome Classification  
Outcome of the event will be defined according to the following:  
• Resolved:  The event has fully resolved at the end of the study. 
• Resolved with sequelae : The event has resolved , but r etained pathological conditions 
resulting from the prior disease or injury.  
• Continuing:  The event is ongoing at the end of the study. 
• Death:  This event is determined to be the cause of death.  
14.[ADDRESS_1056823]’s medical record.  
Device deficiencies are NOT to be reported as AEs. However, if there is an AE  that results from a 
device deficiency, that specific event would be recorded on the appropriate  CRF.  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 34 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056824]’s signs and 
symptoms . AEs will be monitored until a subject completes the study unless the Investigator 
determines the event is related to the investigational device, in which case they will be monitored until resolution if possible . Medical care will be provided, as defined in the informed consent, for 
any AE related to study participation. AEs will be collected on an AE CRF and applicable source 
documentation.  
The following should not be considered an AE:  
• A condition requiring a preplanned procedure unless the condition worsened since 
screen ing 
• A preexisting condition found as a result of screening, unless the condition has worsened 
since enrollment.  
All AEs observed during the course of this study, regardless of severity or relationship to the 
investigational device will be recorded on the appropriate CRF.  
14.[ADDRESS_1056825] under 21 CFR Part 812.46(b) shall report the results of such evaluation to FDA and to all reviewing IRB's and 
participating investigators within [ADDRESS_1056826] as FDA 
requests (21 CFR Part 812.150) . 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 35 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056827] 
their origin in the Declaration of Helsinki, ISO [ZIP_CODE]:2011 (Clinical Investigation of Medical 
Devices for Human Subjects – Good Clinical Practice), ICH -GCP, and any regional or national 
regulations, as appropriate. 
This may include an inspection by [CONTACT_770121]/or Regulatory Authority 
representatives at any time. The investigator must agree to the inspection of study- related records 
by [CONTACT_121352]/  Motus GI  representatives and must allow direct access to source 
documents to the R egulatory Authority/  Motus GI  representatives . Regulatory Authority 
approvals/authorizations/notifications, where required, will also be in place and fully 
documented prior to study start. 
15.[ADDRESS_1056828] the scientific soundness of the Plan or the rights, safety, or welfare of human 
subjects the IRB will also be notified. All other deviations will be reported per the site’s IRB 
deviation policy. Should any deviations from the Investigational Plan occur, these will be reviewed by [CONTACT_770122] . If the event is performed without written 
approval from all parties, the investigator may be terminated from the study. 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 36 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056829] (IRB )/Ethics Com mittee (EC)  
Documented approval from the appropriate Institutional Review Board (IRB)  and Ethics 
Committee (EC)  will be obtained for all participating centers prior to study start, according to 
ICH GCP, local laws, regulations, and organization. When neces sary, an extension, amendment,  
or renewal of the IRB/EC approval must be obtained. The IRB/EC must supply to the sponsor a 
list of the IRB  membership and a statement to confirm that the IRB/EC is organized and operates 
according to GCP and applicable laws and regulations.  
15.[ADDRESS_1056830] the IRB/EC written approval of the 
ICF and any other written information to be provided to subjects . The written approval of the 
IRB/EC together with the approved ICFs  must be filed in the study files.  
The process of obtaining informed consent must be in accordance with applicable regulatory 
requirement(s) and must adhere to GCP and to the ethical principles originating in the 
Declaratio n of Helsinki . Written informed consent must be obtained before any study specific 
procedure takes place. Participation in the trial and date of informed consent given by [CONTACT_770123]. 
15.[ADDRESS_1056831] will be kept confidential and, to the extent permitted by [CONTACT_770124] d/or regulations, will not be made publicly available.  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 37 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056832] initials serial number will be appointed (e.g. 
AAA, BBB) . Study findings stored on a computer will be stored in accordance with local data 
protection laws . The subjects will be informed in writing that represe ntatives of the sponsor, 
IRB/EC or Regulatory Authorities may inspect their medical records to verify the information 
collected, and that all personal information made available for inspection will be handled in 
strictest confidence and in accordance with local data protection laws . Subjects will also be 
informed that information regarding the study that does not include subject identifiers will be posted on clinicaltrials.gov. 
If the results of the trial are published, the subject’s identity will remain co nfidential.  
The investigator will maintain a list to enable subjects’ records to be identified.  
15.[ADDRESS_1056833] to the sponsor 45 days in advance of submission in 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 38 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 38 of 44 
 
 
 
order to obtain approval prior to submission of the final version for publication. This will be 
reviewed pr omptly and approval will not be withheld unreasonably. In case of a difference of 
opi[INVESTIGATOR_477675](s), the contents of the publication will be discussed in order to find a solution which satisfies both parties. 
Disclosure of involvement in a publication (e.g., sponsor of the study; collection, analysis, and 
interpretation of data; professional writing assistance) must be as specified by [CONTACT_770125] -specific 
policies, submission requirements, and prevailing editorial standards, in addition to those specified by [CONTACT_231016]. Authors must ensure that an 
acknowledgement/disclosure statement is included in the body of the manuscript for Motus GI  to 
review for accuracy . All authors mus t also disclose financial or personal affiliations that could be 
considered conflicts of interest as per journal requirements.  
16.[ADDRESS_1056834] study data, 
subjects’ m edical records, and CRFs in accordance with current ICH GCPs and the respective 
local and national government regulations and guidelines (if applicable).The Study Investigator 
and the investigating site will permit authorized clinical research personnel an d clinical monitors 
from Motus GI  and/or designee(s) employed by [CONTACT_770126], IRB  
decisions, and Investigator , clinical site records , and facilities  relevant to this study at regular 
intervals throughout the study per the monitoring plan. Additionally, subject charts and clinical records will be requested and reviewed so that protocol adherence and source documentation can 
be verified . The accuracy and quality of the data obtained from the investigator and maintained 
by [CONTACT_770127] b e confirmed through a structured program of clinical field auditing and 
internal review detailed in the monitoring plan. In instances where data protection regulations 
prohibit the direct examination of hospi[INVESTIGATOR_232384](s), the 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 39 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 39 of 44 
 
 
 
Investigator will provide another mechanism of access  to allow  source data verification by [CONTACT_429] . Monitoring may be performed with in person visits or remotely, when applicable.  
To ensure the rights, safety, and welfare of study subjects are be ing maintained, the monitor will 
review training records  to ensure all study staff are trained on the study protocol and use of the 
study devices . If the monitor discovers that an investigator is not complying with the signed 
Investigator Agreement, the investigational plan, applicable laws, or any conditions of approval 
imposed by [CONTACT_3488] /EC, the monitor will report to the Sponsor and take such steps 
necessary to promptly secure compliance . If compliance cannot be secured, device shipments to 
the investigator may be discontinued and the investigator’s participation in the investigation 
terminated . The monitor shall also require such an investigator to dispose of or return the device, 
unless this action would jeopardize the rights, safety, or welfare of a subject.  
16.1 Data Collection and Processing 
This study will utilize a  Case Report Form ( CRF s). All data requested on the CRF s are 
considered required. Data points not collected and/or recorded will be considered deviations 
unless othe rwise specified.  
The Principal Investigator [INVESTIGATOR_770107]/her signature [CONTACT_770133] . Changes to data previously submitted to the sponsor will require a new 
signature [CONTACT_3265] [CONTACT_197086]/approve the changes.  
Data review will be performed to identify possible data discrepancies  and queries will be created 
and issued to the site for correction . The site st aff and site investigator  will be responsible for 
resolving all data queries .  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 40 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056835] from the sponsor to the site upon receiving all 
required documents (e.g., approval/favorable opi[INVESTIGATOR_770108]). The sponsor will maintain 
tracking for all shipment documentation. Prior to any shipment, the si te will be informed by [CONTACT_770128], expected arrival date, and content of the shipment. The site 
should confirm receipt of the shipment. The site will file the Sponsor’s Shippi[INVESTIGATOR_770109]’s Study File. 
An Investigator ’s Device Accountability form will be completed and filed in the  Regulatory 
Binder at each site. In case of technical failure, the site will inform the  designated sponsor contact .  
For each dispensed Pure -Vu Oversleeve and WS connector , the following information should be 
recorded:  
• The subject study number  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 41 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 41 of 44 
 
 
 
• Date dispensed  
• Oversleeve Lot Number  
• Work Station Connector Lot Number   
At the termination of the study, all unused study material must be returned with the 
corresponding documentation as  directed by [CONTACT_770129]. 
17.4 Retention  of Records  
All source documents and CRF s will be kept for a period of no less than five years after the later 
of the following dates: the date of which the study is terminated or completed or; the date that the records are no longer required supporting marketing applications. 
17.5 Study Completion/ Terminat ion of  Study  
Motus GI  reserves the right to discontinue the study at any stage, with suitable written notice to 
all investigators  and reviewing IRBs /ECs , following unforeseen events or other factors that do 
not permit continuation of the study. Similarly, investigators may withdraw from the study at any time, subject to providing written notification to Motus GI  [ADDRESS_1056836] follow -up shall  be 
reported to Motus  on the appropriate CRF.  
The appropriate IRB/EC will be notified of discontinuation of the trial for any reason not later 
than 5 working days after  the sponsor makes this determination and not later than 15 days after 
the sponsor recei ves a notice from the IRB/EC and/or regulatory authority. 
 
 
 
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 42 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, [ADDRESS_1056837] Information  
Questions should be directed to Clinical Affairs.  
Clinical Affairs  
Hagit Ephrath  
VP of Health Economics, Regulatory and Clinical Affairs  
Motus  GI Technologies LTD. 
Keren Ha'yesod 22 3902638 
Tirat Carmel, Israel  
Phone: +972 (73) 3243824 
Mobile: +972 (52) 314- 2045 
Email: hagit @motusgi.com   
 
19.0 References  
 
1. Lai E.J. et al.; The [LOCATION_011] Bowel Preparation Scale: A valid and reliable instrument , 
Gastrointestinal Endoscopy ,2009: 69(3 Pt 2): 620–625  
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, 
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, [LOCATION_009]: 
International Agency for Research on Cancer; 2013.  [cited 2014 July 8]. Available from: 
http://globocan.iarc.fr . 
3. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Ca ncer 
Statistics Review, 1975 -2013, National Cancer Institute. Bethesda, 
MD, http://seer.cancer.gov/csr/1975_2013/  based on November 2015 SEER data submission, 
posted to the SEER web site, April 2016.  
4. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26;383(9927):1490- 502. 
5. Yee J, Kim DH, Rosen MP, Lalani T, Carucci LR, Cash BD, et al. ACR Appropriateness Criteria 
Colorectal Cancer Screening. J Am Coll Radiol. 2014 Jun;11(6):543- 51. 
6. Robert E. Clark, Matthew L. Bechtold, et al; Low -volume polyethylene glycol and bisacodyl for 
bowel preparation prior to colonoscopy: a meta -analysis. Annals of Gastroenterology (2013) 26, 
319-324. 
7.  Ness RM, Manam R, Hoen H, Chalasani N. Predictors of  inadequate  
bowel preparation for colonoscopy. Am J Gastroenterol . 2001; 96: 1797- 802. 
  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 43 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 43 of 44 
 
 
 
 
20.0  Appendixes A: Study Design and Schedule of Assessment  
 
 Visit 1  Follow Up  
Days  0 2 Business Days  
 (± 48 hours ) 
Informed Consent  X  
Eligibility assessment (medical records, BMI, etc.)  X  
Medical History, Concomitant Medications, and 
Demographic details  X  
Assessment of patient’s bowel preparation 
questionnaire   X  
*Assessment of patient’s management Directions (filled -in by [CONTACT_099])  X  
Colonoscopy Procedure  X  
Follow Up  X  X 
Adverse Events Reporting X X 
 
*for subjects with inadequate bowel cleansing  level in at least one segment  at baseline.  
  
 
 CONFIDENTIAL  
Document Title:  Document No.   Version  Page 44 of 44 
Evaluation of the bowel cleansing in hospi[INVESTIGATOR_770088] -Vu System  CL00044  4.0  
    
CL00044 Protocol , Version 4 .0; January 30, 201 9  Page 44 of 44 
 
 
 
 
21.0 Appendix B : [LOCATION_011] Bowel Preparation Scale 
 
    
 
 
  
 
    
 
   
 
  
 A: Score 0 - Unprepared colon segment with mucosa not seen due to solid stool that 
cannot be cleared.  
 B: Score 1 -  A portion of the mucosa of the colon segment is seen, but other areas of the 
colon segment are not seen well due to staining, residual stool, and/or opaque liquid. 
 C: Score 2 - A minor amount of residual staining, small fragments of stool, and/or opaque 
liquid are visible, but the mucosa of the colon segment are seen well.  
 D: Score 3 - The entire mucosa of the colon segment is seen well with no residual 
staining, small fragments of stool, or opaque liquid.  
   
